Sotabase

Career

· Software Engineering Manager, ICloud Engineering, Apple2016–
· Software Engineer, ICloud Engineering, Apple2014–2016
· Leverhulme Research Fellow, University of Cambridge2013–2014
· Software Engineer, Acunu2011–2014
· Postdoctoral Research Associate, University of Cambridge2005–2011
· Teaching Associate, Imperial College London2003–2005
· Ph.D., Computer Science (Artificial intelligence), Imperial College London1996–2003
· Marshall Scholar, UCL1995–1996
· M.Sc., Optoelectronics, with distinction (Optical neural networks), UCL1995–1996
· A.B., Chemistry and Physics and Mathematics, summa cum laude, Harvard University1991–1995

Publications (464)

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
The Lancet Oncology · 2016
778
cited
Pancreatic adenocarcinoma.
New England Journal of Medicine · 2014
605
cited
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
JAMA Oncology · 2018
489
cited
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
JAMA Oncology · 2019
430
cited
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Journal of Clinical Oncology · 2016
403
cited
Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection?
Annals of Surgery · 2013
394
cited
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
Cancer Discovery · 2016
362
cited
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Journal of Clinical Oncology · 2016
337
cited
Current management of gallbladder carcinoma.
The Oncologist · 2010
324
cited
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
Nature Reviews Clinical Oncology · 2020
301
cited
The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy.
International Journal of Radiation Oncology, Biology, Physics · 2005
289
cited
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.
Journal of Clinical Oncology · 2016
262
cited
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Clinical Cancer Research · 2021
241
cited
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Journal of Clinical Oncology · 2017
233
cited
Improved planning time and plan quality through multicriteria optimization for intensity-modulated radiotherapy.
International Journal of Radiation Oncology, Biology, Physics · 2012
205
cited
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.
Journal of Clinical Oncology · 2020
204
cited
Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer
The Oncologist · 2017
200
cited
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Clinical Cancer Research · 2015
181
cited
Scanned proton radiotherapy for mobile targets—the effectiveness of re-scanning in the context of different treatment planning approaches and for different motion characteristics
Physics in Medicine and Biology · 2011
175
cited
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
International Journal of Radiation Oncology, Biology, Physics · 2010
167
cited
Sotabase